Non-small cell lung cancer (NSCLC)

Dr. Chandel is working to identify novel pathways underlying KRAS-driven lung cancer. He is testing two pathways, to determine how mitochondria (powerhouses of the cell) and Notch signaling (a pathway often activated in lung cancer that relays information from outside the cell to inside) behave differently in cancer and non-cancer cells.

Dr. Moghaddam is investigating how airway inflammation can lead to lung cancer.  The factor NF-κβ is involved in both inflammation and carcinogenesis. Dr. Moghaddam’s hypothesis is that NF-κβ is a likely candidate for the promotion of lung cancer by inflammation in chronic obstructive pulmonary disease patients.

Previous work of Dr. Eaton and colleagues has demonstrated that mice vaccinated with certain stem cells are 80%-90% protected against the growth of lung tumors injected into the mice as well as protected against the development of lung cancer caused by administration of a carcinogen. The current research is determining whether lung cancer stem cells are selectively destroyed by lymphocytes (immune cells) from vaccinated mice. Dr. Eaton is also determining whether stem cell vaccination  affects the growth of lung tumors in mice that have been genetically engineered to spontaneously develop lung cancer.

Dr. Yendamuri is conducting a clinical trial among stage-1 non-small cell lung cancer patients to confirm a microRNA signature for the prediction of the recurrence of lung cancer after surgery. He then will develop a blood-based microRNA profile for the detection of lung cancer recurrence.

The CHFR gene is a gene that has undergone changes in its DNA. Dr. Brandes is studying how the CHFR gene predicts a non-small cell lung cancer patient’s response to chemotherapy.

Dr. Wigle is investigating the effectiveness of stereotactic radiation therapy (SBRT) versus surgery in patients with compromised pulmonary function. This project is a phase II clinical trial whose results will set the stage for more-definitive phase III trials.

The key proteins driving the growth of new blood vessels in tumors are the vascular endothelial growth factor (VEGF) and its main receptors. Dr. Innocenti is studying how the level of these factors varies in the tumors of non-small cell lung cancer patients. He is also determining whether there is a genetic basis for the difference in their levels and what the role of these proteins in helping patients live longer is.

The PARP protein is a protein that protects cancer cells from being killed by chemotherapy. Dr. Brandes is determining how drugs that stop the PARP protein can be used for targeted therapy of non-small cell lung cancer.

Dr. Borgia is developing a process based on biomarkers derived from tissue and clinical factors such as age, smoking history, histology, and stage of diagnosis of lung cancer. This process will identify which patients with advanced-stage lung cancer will respond to medical treatment and thus qualify for surgery that potentially could cure the cancer.

Dr. Yendamuri is conducting a clinical trial among stage-1 non-small cell lung cancer patients to confirm a microRNA signature for the prediction of the recurrence of lung cancer after surgery.  He then will develop a blood-based microRNA profile for the detection of lung cancer recurrence.